Keros Therapeutics (KROS) Leases (2019 - 2025)
Historic Leases for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $17.5 million.
- Keros Therapeutics' Leases fell 1190.54% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year decrease of 1190.54%. This contributed to the annual value of $19.3 million for FY2024, which is 2554.45% up from last year.
- As of Q3 2025, Keros Therapeutics' Leases stood at $17.5 million, which was down 1190.54% from $18.1 million recorded in Q2 2025.
- Over the past 5 years, Keros Therapeutics' Leases peaked at $19.8 million during Q3 2024, and registered a low of $447000.0 during Q3 2022.
- For the 5-year period, Keros Therapeutics' Leases averaged around $10.1 million, with its median value being $15.0 million (2024).
- Its Leases has fluctuated over the past 5 years, first plummeted by 3614.29% in 2022, then surged by 340536.91% in 2023.
- Keros Therapeutics' Leases (Quarter) stood at $1.1 million in 2021, then soared by 1343.3% to $15.4 million in 2022, then fell by 0.43% to $15.3 million in 2023, then increased by 25.54% to $19.3 million in 2024, then dropped by 9.29% to $17.5 million in 2025.
- Its Leases stands at $17.5 million for Q3 2025, versus $18.1 million for Q2 2025 and $18.7 million for Q1 2025.